Synapse - Works

Results (199)

CML and the WHO: Why?

Editorial

Berman, E.; Shah, N. P.; Deninger, M.; Altman, J. K.; Amaya, M.; Begna, K.; Bhatia, R.; Chan, O.; Collins, R.; Curtin, P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naive myelofibrosis

Journal Article

Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Palandri, F.; Devos, T.; Passamonti, F.; Rampal, R. K.; Mead, A. J.; Hobbs, G.; Scandura, J. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI)

Meeting Abstract

Atallah, E. L.; Mauro, M. J.; Sasaki, K.; Levy, M. Y.; Koller, P. B.; Sadek, I.; Yang, D.; Ruckel-Kumar, J.; Khan, M. H.; Cortes, J. E.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)

Meeting Abstract

Smith, C. C.; Vachhani, P.; Garcia-Manero, G.; Grieselhuber, N. R.; Guru Murthy, G. S.; Bhatia, A.; Arora, J.; Izadi, H.; Fiorino, A.; Rampal, R.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

Meeting Abstract

Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E. M.; Mauro, M. J.; Rampal, R.; Bose, P.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings

Meeting Abstract

Walsh, M. F.; Fiala, E.; Birsoy, O.; Haque, T.; Stein, E. M.; Shukla, N.; Sulis, M. L.; Goldberg, A. D.; Rana, S.; Khurram, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Clonal hematopoiesis in survivors of childhood cancer

Meeting Abstract

Friedman, D. N.; Chan, I. C. C.; Moskowitz, C. S.; Li, S.; Turner, K.; Liu, J.; Bouvier, N.; Walsh, M. F.; Spitzer, B.; Kung, A.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Longitudinal, prospective cardiovascular and metabolic risk in treatment-naive patients with chronic myeloid leukemia in chronic phase (CML-CP) starting tyrosine kinase inhibitor (TKI) therapy in a real-world setting

Meeting Abstract

Moslehi, J. J.; Aras, M. A.; Oehler, V. G.; Thompson, J. E.; McCloskey, J. K.; Heinrich, M. C.; DeGutis, I. S.; Fish, S. M.; Mauro, M. J.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study

Meeting Abstract

Passamonti, F.; Patriarca, A.; Knapper, S.; Rivera, C.; Scandura, J.; Devos, T.; Granacher, N.; Mead, A. J.; Oh, S.; Palmer, J. M.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3

Meeting Abstract

Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save